Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets including India
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Advisory from Apollo Spectra Hospitals highlights hydration, nutrition, and screening as key preventive measures
New purpose-built AI model targets faster R&D cycles and deeper scientific insights across life sciences
One Health-based surveillance model to focus on bird sanctuaries and high-risk human populations
American College of Cardiology and Korean Society of Cardiology convene global experts to address rising cardiometabolic burden
Discussions will focus on how private space stations can improve access, repeatability and commercial feasibility for advanced biotech experiments
The CE Mark builds on the company’s ISO 13485 certification, further strengthening confidence in the platform's safety, quality and performance
Dr Desai argued that the sector is undergoing a structural acceleration in how quickly science turns into treatments
Subscribe To Our Newsletter & Stay Updated